Publications by authors named "N Perdek"
Article Synopsis
- - Vaccine development for SARS-CoV-2 in 2020 was essential for reducing COVID-19 severity, with the U.K. primarily using Pfizer's BNT162b2 and Oxford/AstraZeneca's ChAdOx1-nCoV-19 vaccines during the initial roll-out.
- - A study analyzed the effects of age, sex, BMI, and pre-vaccination antibody levels on immune responses in participants, revealing that younger age and existing antibodies led to stronger antibody responses.
- - Findings showed that the Pfizer vaccine produced higher antibody levels compared to the AstraZeneca vaccine, but age and BMI negatively impacted both cellular and humoral responses to vaccination.
Purpose: Investigating the use of the EORTC bladder cancer (BC) modules by evaluating: (a) study contexts/designs; (b) languages/countries in which the modules were administered; (c) their acceptance by patients/investigators; and (d) their psychometric properties.
Methods: A systematic review was performed with studies from 1998 until 20/10/2021 in five databases. Articles/conference abstracts using the EORTC-QLQBLM30 (muscle invasive BC) and the EORTC-QLQNMIBC24 (previously referred to as QLQ-BLS24; non-muscle invasive BC) were included.
Background: The invasion of Ukraine by Russia in February 2022 has resulted in destruction of healthcare infrastructure and triggered the largest wave of internally displaced populations and refugees since World War Two. Conflicts in transitioned countries such as Ukraine create new non-communicable disease (NCD) challenges, especially for cancer care for refugees and humanitarian assistance in host countries. In the early days, rapid attempts were made to model possible impacts.
View Article and Find Full Text PDFAntibody responses to SARS-CoV-2 vaccines vary for reasons that remain poorly understood. A range of sociodemographic, behavioural, clinical, pharmacologic and nutritional factors could explain these differences. To investigate this hypothesis, we tested for presence of combined IgG, IgA and IgM (IgGAM) anti-Spike antibodies before and after 2 doses of ChAdOx1 nCoV-19 (ChAdOx1, AstraZeneca) or BNT162b2 (Pfizer-BioNTech) in UK adults participating in a population-based longitudinal study who received their first dose of vaccine between December 2020 and July 2021.
View Article and Find Full Text PDFObjective: To determine the effect of population level implementation of a test-and-treat approach to correction of suboptimal vitamin D status (25-hydroxyvitamin D (25(OH)D) <75 nmol/L) on risk of all cause acute respiratory tract infection and covid 19.
Design: Phase 3 open label randomised controlled trial.
Setting: United Kingdom.